Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) Invested Capital (2016 - 2026)

Pharma-Bio Serv filings provide 17 years of Invested Capital readings, the most recent being $10.2 million for Q1 2026.

  • On a quarterly basis, Invested Capital fell 14.65% to $10.2 million in Q1 2026 year-over-year; TTM through Jan 2026 was $10.2 million, a 14.65% decrease, with the full-year FY2025 number at $11.9 million, down 13.13% from a year prior.
  • Invested Capital hit $10.2 million in Q1 2026 for Pharma-Bio Serv, down from $11.9 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $17.4 million in Q1 2022 to a low of $10.2 million in Q1 2026.
  • Median Invested Capital over the past 5 years was $14.2 million (2024), compared with a mean of $14.4 million.
  • Biggest five-year swings in Invested Capital: plummeted 32.26% in 2022 and later increased 0.23% in 2023.
  • Pharma-Bio Serv's Invested Capital stood at $16.6 million in 2022, then fell by 2.6% to $16.1 million in 2023, then fell by 14.95% to $13.7 million in 2024, then decreased by 13.13% to $11.9 million in 2025, then fell by 14.06% to $10.2 million in 2026.
  • The last three reported values for Invested Capital were $10.2 million (Q1 2026), $11.9 million (Q4 2025), and $11.9 million (Q3 2025) per Business Quant data.